CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes. Thus, six FDA-approved commercial CAR-T cell products that target antigens preferentially expressed on malignant B-cells or plasma cells...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2024-02-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://www.mjhid.org/mjhid/article/view/5633 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568866061942784 |
|---|---|
| author | Ugo Testa Patrizia Chiusolo Elvira Pelosi Germana Castelli Giuseppe Leone |
| author_facet | Ugo Testa Patrizia Chiusolo Elvira Pelosi Germana Castelli Giuseppe Leone |
| author_sort | Ugo Testa |
| collection | DOAJ |
| description |
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes. Thus, six FDA-approved commercial CAR-T cell products that target antigens preferentially expressed on malignant B-cells or plasma cells have been introduced in the therapy of B-cell lymphomas, B-ALLs and multiple myeloma.
These therapeutic successes have triggered the application of CAR-T cell therapy to other hematologic tumors, including T-cell malignancies. However, the success of CAR-T cell therapies in T-cell neoplasms was considerably more limited to the existence of some limiting factors, such as the sharing of mutual antigens between normal T-cells and CAR-T cells, and malignant cells, determining fratricide events and severe T-cell aplasia; contamination of CAR-T cells used for CAR transduction with contaminating malignant T-cells. Allogeneic CAR-T products can avoid tumor contamination but raise other problems related to immunological incompatibility.
In spite of these limitations, there has been significant progress in CD7- and CD5-targeted CAR-T cell therapy of T-cell malignancies in the last few years.
|
| format | Article |
| id | doaj-art-b35f4cf3d27344039cf165fcbbd92692 |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2024-02-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-b35f4cf3d27344039cf165fcbbd926922025-02-03T00:08:23ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062024-02-0116110.4084/MJHID.2024.031CAR-T CELL THERAPY FOR T-CELL MALIGNANCIESUgo Testa0Patrizia Chiusolo1Elvira Pelosi2Germana Castelli3Giuseppe Leone4ISSUniversità Cattolica Sacro Cuore/Policlinico Gemelli. Roma, ItalyIstituto Superiore Sanità, Roma.Istituto Superiore Sanità, Roma.Università Cattolica del Sacro Cuore, Facoltà di Medicina, Roma Italy Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of B-cell lymphoid neoplasia and, in some instances, improved disease outcomes. Thus, six FDA-approved commercial CAR-T cell products that target antigens preferentially expressed on malignant B-cells or plasma cells have been introduced in the therapy of B-cell lymphomas, B-ALLs and multiple myeloma. These therapeutic successes have triggered the application of CAR-T cell therapy to other hematologic tumors, including T-cell malignancies. However, the success of CAR-T cell therapies in T-cell neoplasms was considerably more limited to the existence of some limiting factors, such as the sharing of mutual antigens between normal T-cells and CAR-T cells, and malignant cells, determining fratricide events and severe T-cell aplasia; contamination of CAR-T cells used for CAR transduction with contaminating malignant T-cells. Allogeneic CAR-T products can avoid tumor contamination but raise other problems related to immunological incompatibility. In spite of these limitations, there has been significant progress in CD7- and CD5-targeted CAR-T cell therapy of T-cell malignancies in the last few years. https://www.mjhid.org/mjhid/article/view/5633adults T cell acute lymphoblastic leukemiaCAR-T CellsT-cell lymphoblastic lymphoma |
| spellingShingle | Ugo Testa Patrizia Chiusolo Elvira Pelosi Germana Castelli Giuseppe Leone CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES Mediterranean Journal of Hematology and Infectious Diseases adults T cell acute lymphoblastic leukemia CAR-T Cells T-cell lymphoblastic lymphoma |
| title | CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES |
| title_full | CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES |
| title_fullStr | CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES |
| title_full_unstemmed | CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES |
| title_short | CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES |
| title_sort | car t cell therapy for t cell malignancies |
| topic | adults T cell acute lymphoblastic leukemia CAR-T Cells T-cell lymphoblastic lymphoma |
| url | https://www.mjhid.org/mjhid/article/view/5633 |
| work_keys_str_mv | AT ugotesta cartcelltherapyfortcellmalignancies AT patriziachiusolo cartcelltherapyfortcellmalignancies AT elvirapelosi cartcelltherapyfortcellmalignancies AT germanacastelli cartcelltherapyfortcellmalignancies AT giuseppeleone cartcelltherapyfortcellmalignancies |